In 3-day marathon, ODAC winnows “dangling” accelerated approvals of PD-1/PD-L1 drugs April 30, 2021Vol.47 No.17By Paul Goldberg
Conversation with The Cancer LetterFree We ask FDA to explain “dangling” accelerated approvals—and this week’s ODAC agenda April 30, 2021Vol.47 No.17By Paul Goldberg
Biden urges Congress to fund ARPA-H as OSTP nominee Eric Lander defines agency’s mission April 30, 2021Vol.47 No.17By Matthew Bin Han Ong
ASCO special awards: Maura Gillison, Arul Chinnaiyan, Joseph Sparano, Banu Arun, Dan Hayes, J Freireich, Crystal Mackall April 30, 2021Vol.47 No.17
New NAS members include Mary Beckerle, Lieping Chen, Alan D’Andrea, Katherine High, Olufunmilayo Olopade, Celeste Simon, Eileen White April 30, 2021Vol.47 No.17
FreeIn the Archives Roswell Park’s Eva Noles and NCI’s Carl Baker: “When I start something, I want to finish it” April 30, 2021Vol.47 No.17
Conversation with The Cancer Letter We ask MIT’s Vander Heiden to delineate science from engineering—and NCI from ARPA-H“The lines are much more blurred in terms of what’s an engineering problem and what’s a basic science problem.” April 23, 2021Vol.47 No.16By Matthew Bin Han Ong and Paul Goldberg
COVID-19 & Cancer Herd immunity is achievable, but it will be tight, Francis Collins, other AACR panelists say April 23, 2021Vol.47 No.16By Alexandria Carolan
Cancer History ProjectFreeGuest Editorial Chernobyl: a 35 year follow up on long-term health effects April 23, 2021Vol.47 No.16By Robert Peter Gale
FreeIn the Archives Vincent T. DeVita, Jr. on the National Cancer Act: “Money does buy ideas” April 23, 2021Vol.47 No.16
